Heparine Calcique Panpharma (Heparin Calcium)

Heparine Calcique Panpharma is employed in clinical settings to reduce the risk of clot formation in several high‑risk situations.

• Prevention of deep vein thrombosis (DVT) in patients undergoing orthopedic or prolonged immobilization.
• Prophylaxis of pulmonary embolism (PE) following major surgery or trauma.
• Treatment of established venous thromboembolism, including DVT and PE.
• Anticoagulant support during cardiac or vascular surgery to prevent intra‑operative clotting.
• Use in patients with a history of recurrent thrombotic events when oral anticoagulants are contraindicated.

Heparine Calcique Panpharma may cause a range of adverse reactions, most of which are related to its anticoagulant activity.

Common

• Minor bruising or bleeding at the injection site.
• Small amounts of nosebleed or gum bleeding.
• Mild headache.
• Transient elevation of liver enzymes.

Serious

• Severe or uncontrolled bleeding, including gastrointestinal or intracranial hemorrhage.
• Allergic reactions such as rash, itching, or anaphylaxis.
• Thrombocytopenia (low platelet count) potentially leading to bleeding.
• Spinal or epidural hematoma after neuraxial procedures.

Before initiating Heparine Calcique Panpharma, clinicians should evaluate patient-specific factors to minimize bleeding risk and ensure safe use.

• Assess baseline coagulation parameters (e.g., aPTT, platelet count) and renal function.
• Review history of heparin-induced thrombocytopenia (HIT) or hypersensitivity to heparin.
• Adjust dose or avoid use in patients with active bleeding, recent major surgery, or uncontrolled hypertension.
• Use caution in pregnant or lactating women; benefits must outweigh potential risks.
• Monitor for signs of bleeding or thrombocytopenia during therapy.
• Consider dose reduction in elderly or low‑body‑weight patients.

Heparine Calcique Panpharma can interact with other medications that affect hemostasis or share metabolic pathways, requiring careful management.

Avoid

• Concurrent use of other anticoagulants (e.g., warfarin, direct oral anticoagulants) unless specifically directed.
• Combination with antiplatelet agents such as aspirin, clopidogrel, or NSAIDs in high‑bleeding‑risk patients.
• Simultaneous administration of fibrinolytic drugs (e.g., alteplase) without close monitoring.

Use with caution

• Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may increase gastrointestinal bleeding risk.
• Certain antibiotics (e.g., quinolones) that can potentiate anticoagulant effects.
• Herbal supplements such as ginkgo biloba, garlic, or high‑dose vitamin E.
• Renal impairment that may affect drug clearance.